CCCC
C4 Therapeutics, Inc.
There isn't enough reported data to score CCCC yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CCCC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
CCCC's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CCCC PE Valuation
CCCC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CCCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CCCC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CCCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.63 | +$1.05 |
| Q2 2026 | -$0.91 | +$0.68 |
| Q1 2026 | -$1.10 | +$0.38 |
| Q4 2025 | -$1.27 | +$0.25 |
| Q3 2025 | -$1.68 | +$0.02 |
| Q2 2025 | -$1.59 | +$0.31 |
| Q1 2025 | -$1.48 | +$0.89 |
| Q4 2024 | -$1.52 | +$1.15 |
CCCC is still losing money, but far less than before: $0.63 per share over the past year, against $8.62 at its worst in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CCCC on earnings quality, reporting a profit while its opponent remains loss making.
CCCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.5M | -25% |
| Q2 2026 | $6.6M | +2.8% |
| Q1 2026 | $6.2M | -15% |
| Q4 2025 | $11M | +113% |
| Q3 2025 | $11.2M | -27% |
| Q2 2025 | $6.5M | -46% |
| Q1 2025 | $7.2M | +138% |
| Q4 2024 | $5.2M | +59% |
CCCC's revenue is growing: $8M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -290% | +16 points |
| Q2 2026 | -398% | +43 points |
| Q1 2026 | -452% | -49 points |
| Q4 2025 | -210% | +518 points |
| Q3 2025 | -306% | -123 points |
| Q2 2025 | -441% | -262 points |
| Q1 2025 | -403% | +657 points |
| Q4 2024 | -728% | +419 points |
CCCC's operating margin was −290% last quarter, up 16 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CCCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CCCC on profitability, with a higher operating margin.
CCCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26M | +$5.7M |
| Q1 2026 | -$30M | +$3.3M |
| Q4 2025 | -$22.2M | -$4.2M |
| Q1 2025 | -$33.3M | -$15.2M |
| Q4 2024 | -$17.9M | +$6.2M |
| Q1 2024 | -$18.1M | +$15.6M |
| Q4 2023 | -$24.2M | +$6.5M |
| Q1 2023 | -$33.7M | -$6.9M |
CCCC has burned cash in almost every quarter: −$80M over the past year, against −$101M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CCCC on cash generation, producing positive trailing cash flow while its opponent burns cash.
CCCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +5.4M shares |
| 1 year | +88% | +63.5M shares |
| 3 years | +177% | +87M shares |
| 5 years | +210% | +92.2M shares |
| Available history | +690% | +119M shares |
CCCC has 136M diluted shares, up 88% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $39,000 |
| Q2 2026 | — |
| Q1 2026 | $200,000 |
| Q4 2025 | $14,000 |
| Q3 2025 | $24,000 |
| Q2 2025 | — |
| Q1 2025 | $155,000 |
| Q4 2024 | — |
CCCC has spent almost nothing on buybacks in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CCCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CCCC Net Leverage
CCCC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CCCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 27.4 | Neutral |
CCCC's weekly RSI is 42 (neutral) and its Stochastic is 27 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CCCC PE vs Healthcare Sector
CCCC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CCCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.02 | 8.3% below |
| 20 week MA | $3.48 | 20% below |
| 50 week MA | $3.07 | 9.8% below |
| 100 week MA | $2.72 | 1.8% above |
| 200 week MA | $3.77 | 27% below |
CCCC's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CCCC on trend strength, trading above more of its moving averages.
CCCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.5 | $35.4 | +39% |
| 2021 | $35.4 | $33.4 | -5.8% |
| 2022 | $33.4 | $6.08 | -82% |
| 2023 | $6.08 | $5.65 | -7.1% |
| 2024 | $5.65 | $3.79 | -33% |
| 2025 | $3.79 | $2.12 | -44% |
| 2026 YTD | $2.12 | $2.77 | +31% |
CCCC has finished five years in a row lower, and it's up 31% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CCCC on returns for 2026, with the stronger performance.